Cargando…

Early Assessment of Chemotherapy Response in Advanced Non-Small Cell Lung Cancer with Circulating Tumor DNA

SIMPLE SUMMARY: An early assessment of response to treatment is crucial to informing appropriate therapeutic management. Using a plasma-only strategy, we measured changes in circulating tumor DNA (ctDNA) levels after one or two cycles of chemotherapy in 92 patients with advanced non-small-cell lung...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yaung, Stephanie J., Woestmann, Corinna, Ju, Christine, Ma, Xiaoju Max, Gattam, Sandeep, Zhou, Yiyong, Xi, Liu, Pal, Subrata, Balasubramanyam, Aarthi, Tikoo, Nalin, Heussel, Claus Peter, Thomas, Michael, Kriegsmann, Mark, Meister, Michael, Schneider, Marc A., Herth, Felix J., Wehnl, Birgit, Diehn, Maximilian, Alizadeh, Ash A., Palma, John F., Muley, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139958/ https://www.ncbi.nlm.nih.gov/pubmed/35626082 http://dx.doi.org/10.3390/cancers14102479

Ejemplares similares

A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma
por: Budczies, Jan, et al.
Publicado: (2021)

Plasma-based longitudinal mutation monitoring as a potential predictor of disease progression in subjects with adenocarcinoma in advanced non-small cell lung cancer
por: Jiang, John, et al.
Publicado: (2020)

Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer
por: Magios, Nikolaus, et al.
Publicado: (2021)

Deep Learning for the Classification of Small-Cell and Non-Small-Cell Lung Cancer
por: Kriegsmann, Mark, et al.
Publicado: (2020)

Oligoprogressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 Inhibitors
por: Rheinheimer, Stephan, et al.
Publicado: (2020)

Deciphering the immunosuppressive tumor microenvironment in ALK- and EGFR-positive lung adenocarcinoma
por: Budczies, Jan, et al.
Publicado: (2021)

Major clinical benefit from adjuvant chemotherapy for stage II–III non-small cell lung cancer patients aged 75 years or older: a propensity score-matched analysis
por: Blasi, Miriam, et al.
Publicado: (2022)

Impact of Comorbidities on Mortality in Patients with Idiopathic Pulmonary Fibrosis
por: Kreuter, Michael, et al.
Publicado: (2016)

Glycodelin as a Serum and Tissue Biomarker for Metastatic and Advanced NSCLC
por: Schneider, Marc A., et al.
Publicado: (2018)

Conventional and semi-automatic histopathological analysis of tumor cell content for multigene sequencing of lung adenocarcinoma
por: Kazdal, Daniel, et al.
Publicado: (2021)

Glycodelin is a potential novel follow-up biomarker for malignant pleural mesothelioma
por: Schneider, Marc A., et al.
Publicado: (2016)

CT characteristics in pulmonary adenocarcinoma with epidermal growth factor receptor mutation
por: Zhao, Jing, et al.
Publicado: (2017)

Diagnostik granulomatöser Erkrankungen mit Lungenbefall
por: Piel, Stella, et al.
Publicado: (2017)

Novel Liquid Biomarker Panels for A Very Early Response Capturing of NSCLC Therapies in Advanced Stages
por: Janke, Florian, et al.
Publicado: (2020)

Germline Genetic Variants of the Renin-Angiotensin System, Hypoxia and Angiogenesis in Non-Small Cell Lung Cancer Progression: Discovery and Validation Studies
por: Catarata, Maria Joana, et al.
Publicado: (2020)

Pathways regulating the expression of the immunomodulatory protein glycodelin in non-small cell lung cancer
por: Weber, Rebecca, et al.
Publicado: (2018)

Role of Synaptophysin, Chromogranin and CD56 in adenocarcinoma and squamous cell carcinoma of the lung lacking morphological features of neuroendocrine differentiation: a retrospective large-scale study on 1170 tissue samples
por: Kriegsmann, Katharina, et al.
Publicado: (2021)

Histological and molecular plasticity of ALK-positive non-small-cell lung cancer under targeted therapy: a case report
por: Ball, Markus, et al.
Publicado: (2022)

Interstitielle Lungenerkrankungen: Klassifikation, Differenzialdiagnostik und therapeutische Ansätze bei einer heterogenen Gruppe chronischer Lungenerkrankungen
por: Lederer, Christoph, et al.
Publicado: (2023)

Interstitielle Lungenerkrankungen: Klassifikation, Differenzialdiagnostik und therapeutische Ansätze bei einer heterogenen Gruppe chronischer Lungenerkrankungen
por: Lederer, Christoph, et al.
Publicado: (2023)

Cell-type specific gene expression profiles of leukocytes in human peripheral blood
por: Palmer, Chana, et al.
Publicado: (2006)

Comprehensive serial biobanking in advanced NSCLC: feasibility, challenges and perspectives
por: Wessels, Sabine, et al.
Publicado: (2020)

Transmembrane serine protease 2 is a prognostic factor for lung adenocarcinoma
por: Schneider, Marc A., et al.
Publicado: (2022)

Plasma-Based Measurements of Tumor Heterogeneity Correlate with Clinical Outcomes in Metastatic Colorectal Cancer
por: Yaung, Stephanie J., et al.
Publicado: (2022)

Prognostic Impact of CT-Quantified Muscle and Fat Distribution before and after First-Line-Chemotherapy in Lung Cancer Patients
por: Nattenmüller, Johanna, et al.
Publicado: (2017)

AURKA, DLGAP5, TPX2, KIF11 and CKAP5: Five specific mitosis-associated genes correlate with poor prognosis for non-small cell lung cancer patients
por: Schneider, Marc A., et al.
Publicado: (2017)

Intratumoral Heterogeneity and Immune Modulation in Lung Adenocarcinoma in Female Smokers and Never Smokers
por: Trefzer, Timo B., et al.
Publicado: (2022)

Circulating tumor DNA as a therapy response marker in metastatic colorectal cancer
por: Ma, Xiaoju Max, et al.
Publicado: (2022)

FAM83A and FAM83B as Prognostic Biomarkers and Potential New Therapeutic Targets in NSCLC
por: Richtmann, Sarah, et al.
Publicado: (2019)

Deep learning for the detection of anatomical tissue structures and neoplasms of the skin on scanned histopathological tissue sections
por: Kriegsmann, Katharina, et al.
Publicado: (2022)

Corrigendum: Deep learning for the detection of anatomical tissue structures and neoplasms of the skin on scanned histopathological tissue sections
por: Kriegsmann, Katharina, et al.
Publicado: (2023)

Treatment and outcome of patients with metastatic NSCLC: a retrospective institution analysis of 493 patients
por: Reinmuth, Niels, et al.
Publicado: (2013)

Blood-sampling collection prior to surgery may have a significant influence upon biomarker concentrations measured
por: Kahn, Nicolas, et al.
Publicado: (2015)

Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report
por: Blasi, Miriam, et al.
Publicado: (2021)

Serial liquid biopsies for detection of treatment failure and profiling of resistance mechanisms in KLC1–ALK-rearranged lung cancer
por: Dietz, Steffen, et al.
Publicado: (2019)

Data normalization considerations for digital tumor dissection
por: Newman, Aaron M., et al.
Publicado: (2017)

Outcome and prognostic factors of multimodal therapy for pulmonary large-cell neuroendocrine carcinomas
por: Rieber, Juliane, et al.
Publicado: (2015)

Cellular dissociation grading on biopsies of pulmonary squamous cell carcinoma provides prognostic information across all stages and is congruent with resection specimen grading
por: Jesinghaus, Moritz, et al.
Publicado: (2022)

Residual symptoms and lower lung function in patients recovering from SARS-CoV-2 infection
por: Trinkmann, Frederik, et al.
Publicado: (2021)

Fibroblast Growth Factor—14 Acts as Tumor Suppressor in Lung Adenocarcinomas
por: Turkowski, Kati, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_n14tljn5r292i7sr5s167au7mh